Article info

Download PDFPDF
Extended report
A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)

Authors

  1. Correspondence to Dr Kenneth C Kalunian, Rheumatology, Allergy, and Immunology, UC San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093-0943, USA; kkalunian{at}ucsd.edu
View Full Text

Citation

Kalunian KC, Merrill JT, Maciuca R, et al
A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)

Publication history

  • Received June 13, 2014
  • Revised March 6, 2015
  • Accepted March 22, 2015
  • First published June 2, 2015.
Online issue publication 
December 11, 2015

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.